GlassScriptPhysician profile
Youngsoon An
NPI 1174821128
$2,965.98
in general payments reported to CMS, 2019-2025
29 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.36 · 2022: $564 · 2023: $691 · 2024: $680 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,822 · Honoraria: $350 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.19 |
| Honoraria | $350.00 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $350.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $306.18 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $299.22 | 2023-2025 | Opdivo, Pomalyst |
| Celgene Corporation | $230.80 | 2024-2025 | Reblozyl |
| Seagen INC. | $224.97 | 2022-2025 | |
| Daiichi Sankyo INC. | $207.16 | 2021-2024 | Injectafer, Vanflyta, Enhertu |
| Janssen Biotech, INC. | $162.90 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $143.36 | 2024-2025 | Calquence |
| Incyte Corporation | $114.20 | 2025 | Monjuvi |
| Sanofi-Aventis U.S. LLC | $97.31 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $87.10 | 2022 | |
| Genzyme Corporation | $83.76 | 2022 | |
| Alexion Pharmaceuticals, INC. | $67.01 | 2022-2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $64.22 | 2022-2023 | Xpovio |
| Stemline Therapeutics INC. | $57.35 | 2025 | Orserdu |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $54.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.87 | 2024-2025 | Ninlaro |
| Amgen INC. | $52.30 | 2022 | |
| Merck Sharp & Dohme LLC | $44.83 | 2024-2025 | Keytruda |
| Legend Biotech USA INC. | $40.33 | 2024 | |
| Immunocore Limited | $30.00 | 2025 | Kimmtrak |
| Novocure INC. | $29.48 | 2025 | Optune Gio |
| Janssen Pharmaceuticals, INC | $29.08 | 2024 | Xarelto |
| Rigel Pharmaceuticals, INC. | $27.93 | 2024 | Rezlidhia, Tavalisse |
| Taiho Oncology, INC. | $26.94 | 2022 | |
| Servier Pharmaceuticals LLC | $23.29 | 2024 | |
| Chiesi USA, INC. | $21.56 | 2024 | Ferriprox |
| Syndax Pharmaceuticals, INC. | $20.59 | 2025 | Revuforj |
| Shield Therapeutics INC | $17.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youngsoon An listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.